Clinical trials: Diabetic Retinal Disease
Diabetic Retinopathy, Glaucoma, Neovascular
Intravitreal Ranibizumab Injection as Adjuvant in the Treatment of Postvitrectomy Diabetic Vitreous Hemorrhage Accompanied by Neovascular Glaucoma
To determine the efficacy of intravitreal ranibizumab injection as adjuvant therapy in the treatment of postvitrectomy diabetic vitreous hemorrhage (PDVH) accompanied by neovascular glaucoma (NVG) as a means of preventing…
- Trial name
- NCT02647515
- Testing
- ranibizumab
- Volunteers
- 18 people
- Sponsor
- Ruijin Hospital
Diabetic Retinopathy (DR)
Assessment of AI Program 'DRISTi' as a Screening Tool
A study will be conducted to demonstrate that DRISTi will correctly diagnose Diabetic Retinopathy (e.g., mtmDR, PDR, DME) in eyes of patients with diabetes.
- Trial name
- NCT07222293
- Testing
- Fundus Image Grading
- Where
- 2 sites in United States
- Volunteers
- 900 people, healthy volunteers welcome
- Sponsor
- Artelus AI
Diabetic Retinopathy
Diabetic Retinopathy Screening in Private Practice
Introduction: Diabetic mellitus (DM) is a prevalent disease in Hong Kong (HK) and diabetic retinopathy (DR) is one of the most common complications of DM.
- Trial name
- NCT02866734
- Testing
- Free screening group, Pay screening group ($150), Pay screening group ($300)
- Where
- Hong Kong
- Volunteers
- 238 people
- Sponsor
- The University of Hong Kong
Diabetic Retinopathy, Age Related Macular Degeneration
AI-Assisted Detection of Posterior Segment Diseases: DR, AMD, RVO, and Glaucoma
The purpose of this multi-center study is to evaluate the extent to which AI-assisted fundus image interpretation improves the diagnostic performance of ophthalmologists.
- Conditions
- Diabetic Retinopathy, Age Related Macular Degeneration, Retinal Vein Occlusion, Glaucoma
- Trial name
- NCT07318428
- Testing
- VUNO Med-Fundus AI
- Where
- 5 sites in South Korea
- Volunteers
- 10 people
- Sponsor
- Inje University
Retinal Detachment, Vitrectomy
Comparative Study of 1000 Centistoke Versus 5000 Centistoke Silicone Oil for Repair of Complex Retinal Detachments
The purpose of this study is to assess the retinal redetachment rates with 1000 centistoke versus 5000 centistoke silicone oil tamponade for repair of complex retinal detachments.
- Conditions
- Retinal Detachment, Vitrectomy, Proliferative Vitreoretinopathy, Diabetic Retinopathy
- Trial name
- NCT01255293
- Testing
- 1000 centistoke silicone oil, 5000 centistoke silicone oil
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Mid Atlantic Retina
Diabetic Retinal Disease
Longitudinal Study of Retinal Function in Eyes Treated for Diabetic Macular Edema With Anti-VEGF Agents
A considerable hurdle to the development of novel, more effective therapies for diabetic retinal disease is the limited number of primary endpoints available for use in regulatory trials.
- Trial name
- AS (NCT07567833)
- Testing
- Anti-Vascular Endothelial Growth Factor
- Where
- 8 sites in United States
- Volunteers
- 100 people
- Sponsor
- Jaeb Center for Health Research
Cornea, Retina
Spectral-domain Optical Coherence Tomography of the Eye
An increasing number of clinical studies on SD-OCT of ocular pathologies and potential new clinical applications has recently been published in the peer-reviewed literature.
- Conditions
- Cornea, Retina, Refractive Surgery, Macular Edema
- Trial name
- NCT02614625
- Where
- Austria
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Augenabteilung Allgemeines Krankenhaus Linz
Diabetic Macular Edema
Visual Outcomes and the Predictive Factors in Chinese Patients With Diabetic Macular Edema Treated With Ranibizumab
The aim of this study is to evaluate the one-year visual outcome and prognostic factors after intraocular injections of ranibizumab under pro re nata treatment regimen for the patients with diabetic macular edema (DME).
- Trial name
- IVRDME (NCT03973138)
- Testing
- Ranibizumab
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Sun Yat-sen University
Diabetic Retinopathy
Evaluation of Retinal Changes in Systemic Darbepoetin Alpha Treatment in Patients With Diabetes Mellitus
The purpose of this study is to determine whether systemic administration of darbepoetin alpha results in the progression or regression of diabetic macular edema.
- Trial name
- EPOinDR (NCT00704652)
- Where
- Austria
- Volunteers
- 5 people
- Sponsor
- Medical University of Vienna
Proliferative Diabetic Retinopathy
PRP vs Bevacizumab for PDR Treatment
Protocol S by DRCR.net has shown that receive Ranibizumab as anti-vascular endothelial growth factor (anti-VEGF) therapy with deferred panretinal photocoagulation (PRP) are non-inferior to those in eyes that receive standard…
- Trial name
- NCT02705274
- Testing
- Bevacizumab, Panretinal photocoagulation
- Where
- Syria
- Volunteers
- 30 people
- Sponsor
- Marashi Eye Clinic
Does Hyperbaric Chaber Treatment Improve Diabetic Retinopathy
The Effect of Hyperbaric Chamber Treatment on Patients With Diabetic Retinopathy
Diabetic retinopathy (DR) is a common complication of diabetes and is divided into non proliferative DR and proliferative DR. The damage is caused by either macular edema, macular ischemia that can be followed by vascular…
- Trial name
- NCT02235935
- Where
- Israel
- Volunteers
- 40 people
- Sponsor
- Assaf-Harofeh Medical Center
Proliferative Diabetic Retinopathy, Vitreous Hemorrhage
Cryoapplication Versus Anti-VEGF Before Diabetic Vitrectomy
Pars-plana vitrectomy (PPV) is the cornerstone of surgical treatment for eyes with complicated proliferative diabetic retinopathy. Anti-VEGF intravitreal injection before PPV has shown a good effect on surgical outcomes.
- Conditions
- Proliferative Diabetic Retinopathy, Vitreous Hemorrhage, Tractional Retinal Detachment
- Trial name
- NCT05514925
- Testing
- Bevacizumab Injection [Avastin], Peripheral Retinal Cryoapplication
- Where
- Tunisia
- Volunteers
- 60 people
- Sponsor
- Khairallah Moncef
Diabetic Retinopathy
Prediction of Progression of Retinal Ischemia in Diabetes
Diabetes Mellitus (DM) is a major public health problem with significant socioeconomic implications due to its increased prevalence.
- Trial name
- PREDICTION (NCT05581225)
- Where
- Portugal
- Volunteers
- 62 people
- Sponsor
- Association for Innovation and Biomedical Research on Light and Image
Non-proliferative Diabetic Retinopathy
Study to Evaluate the Safety, Tolerability, and Efficacy of OTX-TKI in Subjects With Moderately Severe to Severe Non-proliferative Diabetic Retinopathy
Evaluate the Safety, Tolerability, and Efficacy of OTX-TKI in Subjects with Moderately Severe to Severe Non-proliferative Diabetic Retinopathy
- Trial name
- NCT05695417
- Testing
- OTX-TKI
- Where
- 10 sites in United States
- Volunteers
- 21 people
- Sponsor
- Ocular Therapeutix, Inc.
Proliferative Diabetic Retinopathy
Bevacizumab and Long Acting Gas in Diabetic Vitrectomy
Persistent or recurrent vitreous hemorrhage after vitrectomy for diabetic retinopathy complications is a common occurrence with an incidence of 12% to 63%.
- Trial name
- NCT00656435
- Testing
- Bevacizumab
- Where
- Taiwan
- Volunteers
- 16 people
- Sponsor
- National Taiwan University Hospital
Diabetic Retinopathy
Investigating the Structural and Functional Changes to the Retina Following PRP in Diabetic Retinopathy Patients
Laser therapy is an established method to stabilize and control proliferative diabetic eye disease. Questions on the long-term effect on the retina from these treatments remain to be answered.
- Trial name
- NCT02621580
- Testing
- Pan-Retinal Photocoagulation
- Volunteers
- 24 people
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Nonproliferative Diabetic Retinopathy
Study of the Efficacy and Safety of Intravitreal (IVT) Aflibercept for the Improvement of Moderately Severe to Severe Nonproliferative Diabetic Retinopathy (NPDR)
The primary objective of the study is to assess the efficacy of intravitreal (IVT) aflibercept compared to sham treatment in the improvement of moderately severe to severe nonproliferative diabetic retinopathy (NPDR).
- Trial name
- PANORAMA (NCT02718326)
- Testing
- Intravitreal aflibercept injection [IAI]
- Where
- 89 sites in United States, Germany and 4 more
- Volunteers
- 402 people
- Sponsor
- Regeneron Pharmaceuticals
Age-Related Macular Degeneration
Treatment of Diabetic Macular Edema With 0.5mg Intraocular Ranibizumab (Lucentis)
In this prospective, open-label clinical study is to investigate the behavior of the retinal functions during development of diabetic macular disease (DME) under the influence of Lucentis.
- Trial name
- NCT01638858
- Testing
- Lucentis (Ranibizumab)
- Where
- Germany
- Volunteers
- 25 people
- Sponsor
- University of Luebeck
Diabetic Retinopathy, Age-Related Macular Degeneration (AMD)
Genetics and Markers of Degenerative and Inflammatory Eye Diseases
This study will identify genes that are associated with inflammation or degeneration of the retina (membrane lining the back of the eye that relays vision signals to the brain).
- Conditions
- Diabetic Retinopathy, Age-Related Macular Degeneration (AMD), Uveitis
- Trial name
- NCT00647439
- Where
- United States
- Volunteers
- 609 people, healthy volunteers welcome
- Sponsor
- National Eye Institute (NEI)
Non-proliferative Diabetic Retinopathy
Phase III Study of Compound Danshen Dripping Pills to Treat Diabetic Retinopathy
The purpose of this study is to evaluate the efficacy and safety of Compound Danshen Dripping Pills in patients with diabetic retinopathy(Syndrome Of Qi-Stagnation and Blood Stasis).
- Trial name
- NCT02388984
- Testing
- Compound danshen dripping pills
- Where
- 16 sites in China
- Volunteers
- 480 people
- Sponsor
- Tasly Pharmaceuticals, Inc.